Name: Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs (Video) | JoVE Journal
Uploaded: 2022-12-16T13:40:00.000+00:00
Duration: 10 min 38 s
Description: Learn to generate 3D tumor spheroids from patient-derived primary cancer cells for drug sensitivity testing. This cost-effective method supports personalized oncology research and therapeutic screening in standard labs.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

The collection of human tumor samples used for the primary tumor cell cultures was performed as per institutional review board (IRB)-approved protocols at the Rabin Medical Center with written informed consent from the patients. Patients eligible for participation in the study included male and female adult and pediatric cancer patients with non-metastatic breast, colon, liver, lung, neuroendocrine, ovary, or pancreatic cancer, any pediatric cancer, or any metastatic cancer. The only exclusion criterion was the lack of capacity to provide informed consent.
1. Generation and collection of spheroids
NOTE: The isolation of primary tumor cells can be performed as described by Kodak et al.8. Importantly, primary tumor cells used for generating the spheroids can be derived directly from patient samples obtained by biopsy, resection, etc., or indirectly using tumor samples from patient-derived xenograft (PDX) models, as described by Moskovits et al.9.
<ol>
	<li>Prepare a single-cell suspension of adherent primary tumor cell cultures of 75%-100% confluence by taking a small flask (T25) with a single-cell adherent primary cell culture, removing the cell culture media, washing with PBS, and then adding 1 mL of 1x Accutase (a cell detachment solution) (see the Table of Materials) for 3 min at 37 &#176;C.</li>
	<li>Neutralize the Accutase solution by adding 5 mL of cell culture medium (RPMI-1640 culture medium supplemented with 10% FBS, 1:100 penicillin-streptomycin, 1% non-essential amino acids, and 1% L-glutamine; see the Table of Materials).</li>
	<li>Aspirate the cells with a 10 mL serological pipette, and deposit them in a 15 mL conical tube. Centrifuge the tube at 800 x g for 5 min at room temperature.</li>
	<li>Remove the cell culture medium, add 5 mL of fresh cell culture medium on top of the cell pellet, and mix gently.</li>
	<li>Count the viable cells with a hemocytometer10. To do this, take an aliquot of 50 &#956;L of the cell suspension, and mix it with 50 &#956;L of trypan blue. Count the live cells (the cells that are negative for blue color), and calculate the total number of live cells in the suspension.</li>
	<li>Prepare a &#34;3D culture medium&#34; (a cell culture medium supplemented with 5% basement membrane matrix; see the Table of Materials). 
	NOTE: The &#34;3D culture medium&#34; is liquid-like at room temperature. At 37 &#176;C, the consistency becomes more gel-like (so that the cells stay together), although it can still be pipetted (since it contains only 5% basement membrane matrix).</li>
	<li>Calculate the number of cells needed for the assay and the total volume required; each well must contain 2,000-8,000 cells in 200 &#956;L of medium.</li>
	<li>Prepare a cell suspension with the desired number of cells (e.g., 4,000 cells) in 200 &#956;L of the &#34;3D culture medium&#34; and mix gently with the pipette to ensure a homogenous distribution.</li>
	<li>Transfer the suspension to a pipetting reservoir. Using a multi-channel pipette, add 200 &#956;L of the cell suspension to each well of an ultra-low attachment 96-well plate (see the Table of Materials). Before each collection of the cells, mix the suspension well.</li>
	<li>Centrifuge the plate at 300 x g for 10 min at room temperature to enforce the clustering of the cells, thereby improving the cell aggregation, and incubate the plate at 37 &#176;C in a 5% CO2&#160;humidified incubator.</li>
	<li>Every 2-3 days, refresh the &#34;3D culture medium&#34;. Centrifuge the plate at 300 x g for 10 min at room temperature, gently remove and discard 50% of the medium (100 &#956;L), and add 100 &#956;L of fresh &#34;3D culture medium&#34; to replace the existing solution. Repeat step 1.11, and place the plate back in the 37 &#176;C, 5% CO2&#160;humidified incubator. 
	NOTE: The removal of the medium must be performed when the plate is held at 45&#176;, and the medium must be collected only from the upper part to avoid collecting the cells. A vacuum suction system should not be used. The fresh medium needs to be added slowly and gently in order not to disrupt the spheroids, which will have already started to form.</li>
	<li>Inspect the cells under a microscope every 1-2 days to monitor spheroid formation. Measure the diameter of the spheroids formed using the &#34;scale&#34; tool in the imaging software (see the Table of Materials). 
	NOTE: Microscopic inspection should first reveal irregular round-to-oval bodies that assume a spheroid shape as time progresses11,12.
	<ol>
		<li>When the spheroid diameter reaches 100-200 &#956;m, perform the drug efficacy experiments. 
		NOTE: The drug efficacy experiments are performed when the spheroids reach this diameter as, at that time, the majority of the cells are proliferating, which is conducive to evaluating the response to treatment. Larger diameter spheroids contain a necrotic core and a quiescent layer11,12, resulting in a smaller proportion of proliferating cells that respond to treatment.</li>
	</ol>
	</li>
	<li>For spheroid collection, use a 1,000 &#956;L pipette to collect the spheroids from each well, and deposit them into a 15 mL conical tube. 
	NOTE: Spheroids are inherently fragile and require gentle handling. When transferring the medium with the spheroids into the conical tube, hold the tube at 45&#176;, and pipette slowly on the wall of the tube. Spheroids are visible to the eye.</li>
	<li>Centrifuge the conical tube at 300 x g for 5 min at room temperature, and carefully aspirate and discard the supernatant using a pipette.</li>
	<li>Add 0.5 mL of the cell culture medium, and resuspend the pellet well but gently. Avoid making bubbles.</li>
	<li>Perform spheroid counting following the steps below.
	<ol>
		<li>Use a 96-well plate and draw a plus sign on the underside of a well to divide the well into quadrants (to help track the counting).</li>
		<li>Add 50 &#956;L of the suspension to the well, and count the spheroids manually under the microscope (using a 10x objective lens).</li>
		<li>Count the spheroids in each quadrant, be careful not to double count, and calculate the total number of spheroids in the well. 
		NOTE: For accuracy of the counting, count at least 50 spheroids in a well. If there are less than 50 spheroids, gently mix the suspension to ensure homogenous distribution, and count again using a larger volume of the suspension added to a new well. Alternatively, if there are less than 50 spheroids in a well, the spheroids can be centrifuged and resuspended gently in a volume of &#60;0.5 mL. If there are over 100 spheroids, add cell culture medium to the spheroid suspension, mix gently, and recount.</li>
		<li>Calculate the spheroid concentration (spheroid count/counting volume [&#956;L]), and then calculate the total number of spheroids in the suspension (spheroid concentration &#215; total volume).</li>
	</ol>
	</li>
</ol>
2. Drug efficacy assay (MTT assay)
NOTE: For details, please see van Meerloo et al.13. Also, for the MTT assay, only the cell culture medium and not the &#34;3D culture medium&#34; must be used (adding the basement membrane matrix is not necessary and could potentially interfere with the MTT assay).
<ol>
	<li>In a new tube, prepare a spheroid suspension at a concentration of 200 spheroids per 200 &#956;L of cell culture medium (RPMI-1640 culture medium supplemented with 10% FBS, 1:100 penicillin-streptomycin, 1% non-essential amino acids, and 1% L-glutamine).
	<ol>
		<li>For each drug treatment, prepare a stock of spheroids in a 15 mL tube. Calculate the amount needed for each drug by the number of wells needed for repeats: (5-8) &#215; 200 &#956;L. Add the drug to the tube to the final concentration needed. 
		NOTE: Please see the representative results section regarding the drugs used for the present study and their dosage. Also, the commercial details of the drugs are listed in the Table of Materials.</li>
	</ol>
	</li>
	<li>Transfer 200 &#956;L of the spheroid suspension into the wells of an ultra-low attachment 96-well plate, and incubate the plate at 37 &#176;C in a 5% CO2&#160;humidified incubator. Do not use the external rows and columns of the 96-well plate for the assay, as these wells are characterized by increased evaporation, which could lead to increased variability between the repeat experiments; instead, add PBS to these wells. 
	NOTE: It is key that the culture of the spheroids is homogeneous before the culture is aliquoted into the 96-well plate. Also, a control condition (i.e., untreated spheroids) must be included in every experiment.</li>
	<li>After incubating the spheroids with the study drug for 24-72 h, centrifuge the plate at 300 x g for 5 min at room temperature, and gently remove 170 &#956;L of the cell culture medium, leaving 30 &#956;L (which includes the spheroids) at the bottom the well. 
	NOTE: The removal of the 170 &#956;L of cell culture medium must be done carefully, so as not to remove the spheroids. Hold the plate at 45&#176;, and place one hand (wearing a dark glove for contrast) under the wells so that the spheroids are visible (white dots).</li>
	<li>Prepare the MTT solution (0.714 mg/mL in phenol-free RPMI, see the Table of Materials).</li>
	<li>Add 70 &#956;L of MTT solution to each well to a final volume of 100 &#956;L per well (the final MTT concentration in the well will be 0.05 mg per 100 &#956;L). In addition, prepare &#34;Blank&#34; wells with MTT solution without cells. 
	NOTE: MTT is light-sensitive. Therefore, the light in the hood must be switched off, and the tube containing the MTT solution must be covered with aluminum foil.</li>
	<li>Incubate the plate at 37 &#176;C in a 5% CO2&#160;humidified incubator for 3-4 h until a change in the color of the solution in the wells (purple color represents live cells) is observed.</li>
	<li>When a change is observed, add 100 &#956;L of stop solution (0.1N HCl in isopropanol) to each well, and gently mix the content of the wells without creating bubbles.</li>
	<li>Read the absorbance of the plate in a Fluorometer-ELISA reader (see the Table of Materials) at a wavelength of 570 nm and a background wavelength of 630-690 nM. 
	NOTE: If the available Fluorometer-ELISA reader cannot read the ultra-low attachment 96-well plate, transfer the content of each well to a corresponding flat-bottom 96-well plate.</li>
	<li>Calculate the cell viability following the steps below.
	<ol>
		<li>For each well, calculate the &#34;specific signal&#34; (&#34;specific signal&#34; = the signal at 570 nm - the signal at 630-690 nm). Then, calculate the average value of the &#34;Blank&#34; wells, and subtract this value from each well.</li>
		<li>Calculate the average of the &#34;specific signals&#34; in the control wells that contain cells that were not treated with the study drug (&#34;AV-SS-unt&#34;).</li>
		<li>Calculate the viability (percentage) of cells in each well relative to the wells with untreated cells. 
		NOTE: Viability = (specific signal in each well/&#34;AV-SS-unt&#34;) &#215; 100</li>
	</ol>
	</li>
</ol>
3. Monitoring and analyzing the morphological changes in the spheroids
NOTE: As for the MTT assay, only the cell culture medium and not the &#34;3D culture medium&#34; should be used in this evaluation (adding the basement membrane matrix is not necessary and could potentially interfere with the analysis).
<ol>
	<li>After counting the spheroids, dilute the suspension in cell culture medium (RPMI-1640 culture medium supplemented with 10% FBS, 1:100 penicillin-streptomycin, 1% non-essential amino acids, and 1% L-glutamine) to approximately 1-2 spheroids per 20 &#956;L.</li>
	<li>Put 80 &#956;L of cell culture medium into the wells of an ultra-low attachment 96-well plate, and then add 20 &#956;L of the spheroid suspension to the wells. 
	NOTE: The wells will, therefore, contain 1-2 spheroids in a volume of 100 &#956;L.</li>
	<li>Carefully check the wells under the microscope, and mark the wells that contain one spheroid, as they will be used for this analysis.</li>
	<li>Prepare the study drug in a concentration that is two-fold the concentration of interest. Add 100 &#956;L of the drug solution to the relevant wells (the total concentration in the well will then be 1x).</li>
	<li>Capture an image of each well at Day 0 (before adding the study drug) and use the &#34;scale&#34; tool in the imaging software (see the Table of Materials) to determine the diameters of the spheroids.</li>
	<li>Incubate the plate at 37 &#176;C in a 5% CO2&#160;humidified incubator, and examine the morphology and measure the diameter of the spheroids (using the &#34;scale&#34; tool) daily for 3-7 days, depending on when the drug effect is observed (e.g., cell dissemination, invasive pods, structure destruction, etc.).</li>
	<li>At the end of the experiment, plot the changes in spheroid diameters (relative to Day 0) over time. 
	NOTE: Change (percentage) = (spheroid diameter at a specific day/the diameter of that spheroid at Day 0) &#215; 100</li>
</ol>

<ol><li>Katt, M. E., Placone, A. L., Wong, A. D., Xu, Z. S., Searson, P. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((In+vitro+tumor+models%3A+Advantages%2C+disadvantages%2C+variables%2C+and+selecting+the+right+platform%5BTitle%5D)+AND+%22Frontiers+in+Bioengineering+and+Biotechnology%22%5BJournal%5D)">In vitro tumor models: Advantages, disadvantages, variables, and selecting the right platform.</a> Frontiers in Bioengineering and Biotechnology. 4, 12(2016).</li>
<li>Yoshida, G. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Applications+of+patient-derived+tumor+xenograft+models+and+tumor+organoids%5BTitle%5D)+AND+%22Journal+of+Hematology+%26+Oncology%22%5BJournal%5D)">Applications of patient-derived tumor xenograft models and tumor organoids.</a> Journal of Hematology & Oncology. 13 (1), 4(2020).</li>
<li>Ledur, P. F., Onzi, G. R., Zong, H., Lenz, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Culture+conditions+defining+glioblastoma+cells+behavior%3A+What+is+the+impact+for+novel+discoveries%5BTitle%5D)+AND+%22Oncotarget%22%5BJournal%5D)">Culture conditions defining glioblastoma cells behavior: What is the impact for novel discoveries.</a> Oncotarget. 8 (40), 69185-69197 (2017).</li>
<li>Richter, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((From+donor+to+the+lab%3A+A+fascinating+journey+of+primary+cell+lines%5BTitle%5D)+AND+%22Frontiers+in+Cell+and+Developmental+Biology%22%5BJournal%5D)">From donor to the lab: A fascinating journey of primary cell lines.</a> Frontiers in Cell and Developmental Biology. 9, 711381(2021).</li>
<li>Esparza-Lopez, J., Martinez-Aguilar, J. F., Ibarra-Sanchez, M. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Deriving+primary+cancer+cell+cultures+for+personalized+therapy%5BTitle%5D)+AND+%22Revista+de+Investigacio%CC%81n+Cli%CC%81nica%22%5BJournal%5D)">Deriving primary cancer cell cultures for personalized therapy.</a> Revista de Investigación Clínica. 71 (6), 369-380 (2019).</li>
<li>Choi, J. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((In+vitro+human+cancer+models+for+biomedical+applications%5BTitle%5D)+AND+%22Cancers%22%5BJournal%5D)">In vitro human cancer models for biomedical applications.</a> Cancers. 14 (9), 2284(2022).</li>
<li>Eglen, R. M., Randle, D. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Drug+discovery+goes+three-dimensional%3A+Goodbye+to+flat+high-throughput+screening%5BTitle%5D)+AND+%22Assay+and+Drug+Development+Technologies%22%5BJournal%5D)">Drug discovery goes three-dimensional: Goodbye to flat high-throughput screening.</a> Assay and Drug Development Technologies. 13 (5), 262-265 (2015).</li>
<li>Kodack, D. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Primary+patient-derived+cancer+cells+and+their+potential+for+personalized+cancer+patient+care%5BTitle%5D)+AND+%22Cell+Reports%22%5BJournal%5D)">Primary patient-derived cancer cells and their potential for personalized cancer patient care.</a> Cell Reports. 21 (11), 3298-3309 (2017).</li>
<li>Moskovits, N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Palbociclib+in+combination+with+sunitinib+exerts+a+synergistic+anti-cancer+effect+in+patient-derived+xenograft+models+of+various+human+cancers+types%5BTitle%5D)+AND+%22Cancer+Letters%22%5BJournal%5D)">Palbociclib in combination with sunitinib exerts a synergistic anti-cancer effect in patient-derived xenograft models of various human cancers types.</a> Cancer Letters. 536, 215665(2022).</li>
<li>Ricardo, R., Phelan, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Counting+and+determining+the+viability+of+cultured+cells%5BTitle%5D)+AND+%22Journal+of+Visualized+Experiments%22%5BJournal%5D)">Counting and determining the viability of cultured cells.</a> Journal of Visualized Experiments. (16), e752(2008).</li>
<li>Brajša, K., Trzun, M., Zlatar, I., Jelić, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Three-dimensional+cell+cultures+as+a+new+tool+in+drug+discovery%5BTitle%5D)+AND+%22Periodicum+Biologorum%22%5BJournal%5D)">Three-dimensional cell cultures as a new tool in drug discovery.</a> Periodicum Biologorum. 118 (1), 59-65 (2016).</li>
<li>Han, S. J., Kwon, S., Kim, K. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Challenges+of+applying+multicellular+tumor+spheroids+in+preclinical+phase%5BTitle%5D)+AND+%22Cancer+Cell+International%22%5BJournal%5D)">Challenges of applying multicellular tumor spheroids in preclinical phase.</a> Cancer Cell International. 21 (1), 152(2021).</li>
<li>van Meerloo, J., Kaspers, G. J., Cloos, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cell+sensitivity+assays%3A+The+MTT+assay%5BTitle%5D)+AND+%22Methods+in+Molecular+Biology%22%5BJournal%5D)">Cell sensitivity assays: The MTT assay.</a> Methods in Molecular Biology. 731, 237-245 (2011).</li>
<li>Walzl, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+resazurin+reduction+assay+can+distinguish+cytotoxic+from+cytostatic+compounds+in+spheroid+screening+assays%5BTitle%5D)+AND+%22Journal+of+Biomolecular+Screening%22%5BJournal%5D)">The resazurin reduction assay can distinguish cytotoxic from cytostatic compounds in spheroid screening assays.</a> Journal of Biomolecular Screening. 19 (7), 1047-1059 (2014).</li>
</ol>

The authors have nothing to disclose.

The present protocol describes a simple method for generating 3D primary cell cultures (spheroids) derived from human tumor samples. These spheroids can be used for various analyses, including evaluating potential drug candidates and drug combinations, identifying potential biomarkers or therapeutic targets, and investigating the mechanisms of response and resistance. The protocol uses either primary tumor cells derived directly from patient samples or tumor cells from PDX models, which can be established using patient s...

In vitro and in vivo studies represent complementary approaches for developing cancer treatments. In vitro models allow for the control of most experimental variables and facilitate quantitative analyses. They often serve as low-cost screening platforms and can also be used for mechanistic studies1. However, their biological relevance is inherently limited, as such models only partially reflect the tumor microenvironment1. In contrast, in vivo models, such as patient-derived xenografts (PDX), capture the complexity of the tumor microenvironment and are more suitable for translational studies and individualizing treatment in patients (i.e., investigating the response to drugs in a model derived from an individual patient)1. However, in vivo models are not conducive to high-throughput approaches for drug screening, as the experimental parameters cannot be controlled as tightly as in in vitro models and because their development is time-consuming, labor intensive, and costly1,2.
In vitro models have been available for over 100 years, and cell lines have been available for over 70 years3. During the last several decades, however, the complexity of the available in vitro models of solid tumors has increased dramatically. This complexity ranges from 2-dimensional (2D) culture models (monolayer structures) that are either tumor-derived established cell lines or primary cell lines to the more recent approaches involving 3-dimensional (3D) models1. Within the 2D models, a key distinction is between the established and primary cell lines4. Established cell lines are immortalized; therefore, the same cell line can be used globally over many years, which from a historical perspective, facilitates collaboration, the accumulation of data, and the development of many treatment strategies. However, genetic aberrations in these cell lines accumulate with every passage, thus compromising their biological relevance. Furthermore, the limited number of available cell lines does not reflect the heterogeneity of tumors in patients4,5. Primary cancer cell lines are derived directly from resected tumor samples obtained via biopsies, pleural effusions, or resections. Therefore, primary cancer cell lines are more biologically relevant as they preserve elements of the tumor microenvironment and tumor characteristics, such as intercellular behaviors (e.g., cross-talk between healthy and cancerous cells) and the stem-like phenotypes of cancer cells. However, the replicative capacity of primary cell lines is limited, which leads to a narrow culture time and limits the number of tumor cells that can be used for analyses4,5.
Models using 3D cultures are more biologically relevant than 2D culture models since the in vivo conditions are retained. Thus, 3D culture models preserve the natural cell shape and growth and replicate elements of the tumor environment, such as hypoxia, necrosis, and cell adhesion. The most commonly used 3D models in cancer research include multicellular spheroids, scaffold-based structures, and matrix-embedded cultures4,6,7.
The present protocol generates 3D tumor culture models (multicellular spheroids) from primary cancer cells and evaluates their sensitivity to drugs using two complementary approaches: a cell-viability assay (MTT) and microscopic examinations. The representative results presented herein are from breast and colon cancer; however, this protocol is widely applicable to other solid tumor types (e.g., cholangiocarcinoma, gastric, lung, and pancreatic cancer) and is also cost-effective, as it can be performed in its entirety in a typical cancer research/cell biology lab without relying on specialized equipment. The multicellular spheroids generated using this approach can be used to assess potential drug candidates, identify potential biomarkers or therapeutic targets, and investigate the mechanisms of response and resistance.
This protocol is divided into three sections: (1) the generation, collection, and counting of the spheroids in preparation for their use as a model for testing drug efficacy; (2) MTT assay to assess drug efficacy on the spheroids; and (3) the microscopic evaluation of morphological changes following the treatment of the spheroids with drugs as another approach for evaluating drug efficacy (Figure 1).

<table><tbody><tr><td>5 Fluorouracil</td><td>TEVA Israel</td><td>lot 16c22NA</td><td>Fluorouracil, Adrucil</td></tr><tr><td>Accutase</td><td>Gibco</td><td>A1110501</td><td>StemPro Accutase Cell Dissociation</td></tr><tr><td>Cisplatin</td><td>TEVA Israel</td><td>20B06LA</td><td>Abiplatin,&amp;nbsp;</td></tr><tr><td>Cultrex&amp;nbsp;</td><td>Trevigen</td><td>3632-010-02</td><td>Basement membrane matrix, type 3</td></tr><tr><td>DMSO (dimethyl sulfoxide)</td><td>Sigma Aldrich</td><td>D2650-100ML</td><td></td></tr><tr><td>Fetal bovine serum (FBS)</td><td>Thermo Fisher Scientific</td><td>2391595</td><td></td></tr><tr><td>Flurometer&amp;nbsp;ELISA reader</td><td>Biotek</td><td>Synergy H1</td><td>Gen5 3.11</td></tr><tr><td>Hydrochloric acid (HCl)&amp;nbsp;</td><td>Sigma Aldrich</td><td>320331</td><td>for stop solution</td></tr><tr><td>ImageJ</td><td>National Institutes of Health, Bethesda, MD, USA</td><td>&amp;nbsp;Version 1.52a</td><td>Open-source software ImageJ</td></tr><tr><td>Isopropanol</td><td>Gadot</td><td>P180008215</td><td>for stop solution</td></tr><tr><td>L-glutamine</td><td>Gibco</td><td>1843977</td><td></td></tr><tr><td>MTT&amp;nbsp;</td><td>Sigma Aldrich</td><td>M5655-1G</td><td>3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</td></tr><tr><td>Non-essential amino acids&amp;nbsp;</td><td>Gibco</td><td>11140050</td><td></td></tr><tr><td>Palbociclib&amp;nbsp;&amp;nbsp;</td><td>Med Chem Express</td><td>CAS # 571190-30-2</td><td></td></tr><tr><td>PBS</td><td>Gibco</td><td>14190094</td><td>Dulbecco&#039;s Phosphate Buffered Saline (DPBS)*Without Calcium and Magnesium</td></tr><tr><td>Penicillin&amp;ndash;streptomycin&amp;nbsp;</td><td>Invitrogen</td><td>2119399</td><td></td></tr><tr><td>Phenol-free RPMI 1640</td><td>Biological industries, Israel</td><td>01-103-1A</td><td></td></tr><tr><td>Pippeting reservoir</td><td>Alexred</td><td>RED LTT012025</td><td></td></tr><tr><td>RPMI-1640 culture medium&amp;nbsp;</td><td>Gibco</td><td>11530586</td><td></td></tr><tr><td>Sunitinib</td><td>Med Chem Express</td><td>CAS # 341031-54-7</td><td></td></tr><tr><td>Trastuzumab</td><td>F. Hoffmann - La Roche Ltd, Basel, Switherland</td><td>10172154 IL</td><td>Herceptin</td></tr><tr><td>Trypan blue 0.5% solution</td><td>Biological industries, Israel</td><td>03-102-1B</td><td></td></tr><tr><td>Ultra-low attachment 96 well plate</td><td>Greiner Bio-one</td><td>650970</td><td></td></tr><tr><td>Vinorelbine</td><td>Ebewe</td><td>11733027-03</td><td>Navelbine</td></tr></tbody></table>

establishing 3-dimensional spheroids from patient-derived tumor samples and evaluating their sensitivity to drugs

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Despite remarkable advances in understanding tumor biology, the vast majority of oncology drug candidates entering clinical trials fail, often due to a lack of clinical efficacy. This high failure rate illuminates the inability of the current preclinical models to predict clinical efficacy, mainly due to their inadequacy in reflecting tumor heterogeneity and the tumor microenvironment. These limitations can be addressed with 3-dimensional (3D) culture models (spheroids) established from human tumor samples derived from individual patients. These 3D cultures represent real-world biology better than established cell lines that do not reflect tumor heterogeneity. Furthermore, 3D cultures are better than 2-dimensional (2D) culture models (monolayer structures) since they replicate elements of the tumor environment, such as hypoxia, necrosis, and cell adhesion, and preserve the natural cell shape and growth. In the present study, a method was developed for preparing primary cultures of cancer cells from individual patients that are 3D and grow in multicellular spheroids. The cells can be derived directly from patient tumors or patient-derived xenografts. The method is widely applicable to solid tumors (e.g., colon, breast, and lung) and is also cost-effective, as it can be performed in its entirety in a typical cancer research/cell biology lab without relying on specialized equipment. Herein, a protocol is presented for generating 3D tumor culture models (multicellular spheroids) from primary cancer cells and evaluating their sensitivity to drugs using two complementary approaches: a cell-viability assay (MTT) and microscopic examinations. These multicellular spheroids can be used to assess potential drug candidates, identify potential biomarkers or therapeutic targets, and investigate the mechanisms of response and resistance.

This protocol presents procedures for generating a homogenous culture of spheroids from primary tumor cells, quantitatively evaluating drug efficacy on spheroid culture (MTT assay), and determining the effect of study drugs on spheroid morphology. Data from the representative experiments in spheroids generated from colon and breast cancer cell cultures are presented. Similar experiments were performed using other tumor types, including cholangiocarcinoma, gastric, lung, and pancreatic cancer (data not shown). All the exp...

The present protocol describes generating 3D tumor culture models from primary cancer cells and evaluating their sensitivity to drugs using cell-viability assays and microscopic examinations.

Despite remarkable advances in understanding tumor biology, the vast majority of oncology drug candidates entering clinical trials fail, often due to a ...

establishing-3-dimensional-spheroids-from-patient-derived-tumor

Research

JoVE Journal

Cancer Research

Invasion of surrounding normal tissues is a defining characteristic of malignant tumors. We provide here a simple, semi-automated micro-plate assay of invasion into a natural 3D biomatrix that has been exemplified with a number of models of advanced human cancers.

Three-Dimensional (3D) Tumor Spheroid Invasion Assay

Patient-derived xenografts of glioblastoma multiforme can be miniaturized into living microtumors using 3D human biogel culture system. This in vivo-like 3D tumor assay is suitable for drug response testing and molecular profiling, including kinomic analysis.

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

We describe the evolution of a spheroid-based, three-dimensional in vitro model that enables us to test the current standard of experimental therapy regimens for head and neck squamous cell carcinoma on cell lines, aiming at evaluating therapy susceptibility and resistance on primary cells from human specimens in the future.

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Across a wide variety of disease indications, more physiologically relevant models are being developed and implemented into drug discovery programs. The new model system described here demonstrates how three-dimensional tumor spheroids can be cultured and screened in a high-throughput 1536-well plate-based system to search for new oncology drugs.

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Optical coherence tomography (OCT), a three-dimensional imaging technology, was used to monitor and characterize the growth kinetics of multicellular tumor spheroids. Precise volumetric quantification of tumor spheroids using a voxel counting approach, and label-free dead tissue detection in the spheroids based on intrinsic optical attenuation contrast, were demonstrated.

Longitudinal Morphological and Physiological Monitoring of Three-dimensional Tumor Spheroids Using Optical Coherence Tomography

This protocol describes generation of patient-derived spheroids, and downstream analysis including quantification of proliferation, cytotoxicity testing, flow cytometry, immunofluorescence staining and confocal imaging, in order to assess drug candidates’ potential as anti-neoplastic therapeutics. This protocol supports precision medicine with identification of specific drugs for each patient and stage of disease.

Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells

Here, we present several simple methods for evaluating viability and death in 3D cancer cell spheroids, which mimic the physico-chemical gradients of in vivo tumors much better than the 2D culture. The spheroid model, therefore, allows evaluation of the cancer drug efficacy with improved translation to in vivo conditions.

Assessing Cell Viability and Death in 3D Spheroid Cultures of Cancer Cells

This article demonstrates a standardized method for constructing three-dimensional tumor spheroids. A strategy for spheroid observation and image-based deep-learning analysis using an automated imaging system is also described.

Generation of 3D Tumor Spheroids for Drug Evaluation Studies

Here, we present a method to identify compounds that modulate the ADCC mechanism, an important cancer cell-killing mechanism of antitumor antibodies. The cytotoxic effect of NK cells is measured in breast cancer cell spheroids in the presence of Trastuzumab. Image analysis identifies live and dead killer and target cells in spheroids.

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Here, we establish a metabolic profiling platform integrating three-dimensional (3D) glioma spheroids and imaging-based normalization via extracellular flux analysis. This approach enables more accurate assessment of tumor metabolic responses to drug treatments and provides insights into potential mechanisms of resistance.

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

Learn to generate 3D tumor spheroids from patient-derived primary cancer cells for drug sensitivity testing. This cost-effective method supports personalized oncology research and therapeutic screening in standard labs.

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Explore More Videos